entertainment -WSS

entertainment

author：hotspot 2025-09-27 10:01:29 - browse：3956

a person wearing blue dress conducts a finger prick test on another person in a home setting — coverage from STAT — Adobe

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. Their products aren’t cheap, but in the long term, they pitch to health plans and employers that these digital tools will help cut health care costs by preventing serious complications like amputation and kidney failure.

A systematic review by the Peterson Health Technology Institute found, though, that digital tools used to manage diabetes with the help of finger-stick blood glucose readings don’t result in clinically meaningful improvements over standard care. As a result, they don’t reduce health care spending — they drive it up.

“Most of the solutions in this category do not deliver clinical benefits that justify their cost,” Caroline Pearson, executive director of the institute, told STAT. Despite finding that some populations may benefit, the report concludes that current evidence doesn’t support broader adoption for most products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： As biotech industry slumps, bioscience job market is upside down

focus

WSS

UnitedHealth’s Optum accused of antitrust violations in California

Pediatric cancer treatments threatened by a new FDA policy

Rep. Raul Ruiz on the physician shortage and more

UnitedHealth’s Optum accused of antitrust violations in California

What to make of Biden’s latest efforts on cancer research

Long Covid needs a new name — and a new frame

hotspot

entertainment

leisure time

Psychedelics group wrestles with new pharma identity

Food makers tried to stack nutrition panel with preferred experts

Hepatitis C has a cure — but many Americans still lack access to it

Acelyrin, a rare IPO success, stumbles in its first big test

Psychedelics group wrestles with new pharma identity

The EPA's new lead rule: How one expert crunched the numbers

Malaria cases in Florida and Texas: Here’s what you need to know

IRA could hurt research into orphan drugs for rare diseases

What does generative AI mean for health care? We asked experts

Walmart eyes Medicare Advantage provider ChenMed

explore

How housing is health care on Long Island

Flagship Pioneering launches a new biotech in two countries

Cigna, Humana reportedly in talks to merge

UnitedHealth’s Optum accused of antitrust violations in California

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Diverse clinical trials: Why aren’t we there yet?

knowledge

focus

Wikipedia

hotspot